Newspaper Clipping of Unaudited Financials for 3rd Quarter ended December 21, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Welcure Drugs & Pharmaceuticals has submitted the newspaper advertisement of its unaudited standalone financial results for the quarter and nine months ended December 31, 2025, as required under SEBI listing rules. For Q3 FY26 alone, total income stood at Rs 146.43 lakh (vs Rs 833.80 lakh in Q3 FY25), while net profit after tax was Rs 106.67 lakh (vs Rs 41.50 lakh). For the nine months ended December 2025, total income surged to Rs 36,790.25 lakh (vs Rs 2,455 lakh) and net profit after tax jumped to Rs 4,340.27 lakh (vs Rs 95.56 lakh). EPS for 9M FY26 was Rs 0.76 vs Rs 0.10 in 9M FY25. Results were reviewed by the auditor and approved by the Board on February 12, 2026.
The huge year-on-year jump in nine-month revenue and profits signals a strong scale-up in business operations, though the very low Q3 income (down sharply from the prior-year quarter) suggests the bulk of earnings were booked earlier in the year, which investors should note when assessing run-rate.